Endoxifen Citrate Enteric Coating for Bipolar I Suicide Risk
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for bipolar disorder, such as lithium and valproate, have significant issues with tolerability, efficacy, and high suicide risk, with up to 40-50% of patients not benefiting, and there is a need for improved therapeutic strategies targeting the PKC signaling pathway to reduce suicidal behavior.
Innovation Solution
Administering endoxifen citrate in an enteric-coated tablet at a dose of 2-16 mg once daily for at least 21 days to maintain a therapeutically effective concentration, leveraging its PKC inhibitory action to reduce suicidal behavior in bipolar I disorder patients.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments (lithium, valproate) are administered to bipolar disorder patients, then mood stabilization is achieved, but tolerability issues and high suicide risk persist
Solution Approach 1:
The patent changes the chemical parameter by introducing endoxifen citrate, a metabolite of tamoxifen, as an alternative to conventional mood stabilizers. This parameter change in treatment composition achieves mood stabilization while reducing suicide risk and adverse effects, directly resolving the contradiction between efficacy and safety
Solution Approach 2:
Endoxifen citrate acts as an intermediary substance that modulates the serotonergic system and PKC pathway, providing a mediating mechanism between the patient's neurochemical imbalances and mood regulation. This intermediary approach achieves therapeutic effects without the harmful side effects of conventional treatments
2Reliability
If higher doses of conventional medications are used to improve efficacy, then treatment effectiveness increases, but adverse effects such as sedation, weight gain, and thrombocytopenia worsen
Solution Approach 1:
The patent changes the dosing parameter by administering endoxifen citrate at low doses (2-16 mg once daily), which achieves therapeutic effectiveness without causing the dose-dependent adverse effects seen with conventional medications. This parameter optimization resolves the contradiction between efficacy and tolerability
3Ease of operation
If treatment adherence is improved by using better tolerated agents, then patient compliance increases, but efficacy may be reduced
Solution Approach 1:
The patent changes multiple parameters including chemical structure (endoxifen citrate), dosing frequency (once daily), and dose range (2-16 mg) to achieve a optimal balance where the treatment is both well-tolerated and highly effective, eliminating the need to choose between compliance and efficacy
4Measurement precision
If continuous therapeutic monitoring is implemented to maintain effective concentrations, then treatment precision improves, but treatment complexity and resource requirements increase
Solution Approach 1:
Endoxifen citrate exhibits self-regulating properties where the once-daily dosing regimen maintains therapeutic concentrations without requiring complex monitoring protocols. The drug's pharmacokinetic profile enables self-service maintenance of effective levels, reducing treatment complexity while ensuring therapeutic precision
Data Source
AI summary
A method for managing or decreasing a risk of suicidal behaviour in a patient undergoing treatment of bipolar I disorder is provided. The said method includes maintaining the therapeutically effective concentration of endoxifen by administrating a dose of 2 mg to 16 mg of endoxifen citrate in an enteric coated tablet once per day for at least 21 days.